EDEN PRAIRIE, Minn. / Nov 17, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it expects to close its previously announced acquisition (the “Merger”) of the Company by an affiliate of GTCR LLC (“GTCR”) promptly. In a joint status report filed with the United States... Read More

EDEN PRAIRIE, Minn. / Nov 10, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the “District Court”) has denied a request by the U.S. Federal Trade Commission (the “FTC”) and certain state... Read More

Analysis of the all-comers PROWL Registry demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients with symptomatic limb ischemia, over 40% of whom had symptoms lasting more than two weeks before intervention with the Pounce™ Platform. EDEN PRAIRIE, Minn. / Nov 04, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro... Read More

PROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Updated safety and performance data from 160 patients with symptomatic infrainguinal vessels will be shared. EDEN PRAIRIE, Minn. / Nov 03, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the... Read More

Analysis of 160 patients with acute, subacute, or chronic symptoms of thrombotic limb ischemia receiving thromboemboli removal treatment with the Pounce™ Thrombectomy Platform demonstrated high procedural success across sexes, 91.3% technical success in women. EDEN PRAIRIE, Minn. / Oct 29, 2025 / Business Wire / Surmodics, Inc . (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the... Read More

PROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Results of a sex-specific analysis of 160 patients with symptomatic infrainguinal vessels will be shared. EDEN PRAIRIE, Minn. / Oct 27, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health... Read More

EDEN PRAIRIE, Minn. / Aug 08, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a... Read More

EDEN PRAIRIE, Minn. / Aug 06, 2025 / Business Wire / Surmodics, Inc. ( Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that third quarter of fiscal year 2025 financial results will be released before the market opens on Friday, August 8. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference call... Read More

EDEN PRAIRIE, Minn. / Apr 30, 2025 / Business Wire / Surmodics, Inc . (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2025, and introduced its financial guidance for the fiscal year ending September 30, 2025. Second Quarter Fiscal 2025 Financial Summary Total Revenue of $28.1 million,... Read More

EDEN PRAIRIE, Minn. / Apr 28, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second quarter of fiscal year 2025 financial results will be released before the market opens on Wednesday, April 30. Given the pending acquisition by GTCR, Surmodics will not be hosting a live webcast and conference... Read More

European Journal of Vascular and Endovascular Surgery Publishes Results Showing Comparable Safety and Efficacy of SurVeil™ DCB Despite IN.PACT™ Admiral™ DCB having 75% Higher Paclitaxel Dose. EDEN PRAIRIE, Minn. / Apr 22, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND... Read More

With the addition of the Pounce™ XL Thrombectomy System, indicated for use in 5.5–10 mm peripheral arteries, the fully mechanical Pounce™ Thrombectomy Platform can now remove thrombi or emboli throughout the lower and upper extremities without aspiration, thrombolysis, or capital equipment EDEN PRAIRIE, Minn. / Apr 03, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro... Read More

EDEN PRAIRIE, Minn. / Mar 06, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission’s (“FTC” or the “Agency”) announcement that it will challenge the proposed acquisition of Surmodics (the “Merger”) by funds affiliated with GTCR LLC (“GTCR”),... Read More

With the addition of the Pounce™ XL Thrombectomy System, indicated for use in 5.5–10 mm peripheral arteries, the Pounce™ Thrombectomy Platform can now rapidly remove acute or chronic clot throughout the lower extremity without aspiration, thrombolysis, or capital equipment. EDEN PRAIRIE, Minn. / Feb 03, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic... Read More

EDEN PRAIRIE, Minn. / Jan 30, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2024. First Quarter Fiscal 2025 Financial Summary Total Revenue of $29.9 million, a decrease of 2% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon... Read More

EDEN PRAIRIE, Minn. / Nov 06, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. Fourth Quarter Fiscal 2024 Financial Summary Total Revenue of $33.2 million, an increase of 19% year-over-year Total Revenue excluding SurVeil... Read More

Early subset analysis of 60 patients with acute, subacute, or chronic symptoms of limb ischemia demonstrated 96.8% procedural flow restoration, with 81.7% of subjects not receiving additional thromboemboli removal treatment post Pounce™ System use. EDEN PRAIRIE, Minn. / Oct 30, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care... Read More

The Pounce™ Thrombectomy Platform can now be used to remove clot from peripheral arteries as small as 2mm up to as large as 10 mm in diameter, broadening the platform's clinical utility and significantly expanding its addressable market EDEN PRAIRIE, Minn. / Oct 01, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received... Read More

EDEN PRAIRIE, Minn. / Jul 31, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2024. Third Quarter Fiscal 2024 Financial Summary Total Revenue of... Read More

Access to Premier’s healthcare group purchasing organization (GPO) expected to expand national market reach for Surmodics endovascular thrombectomy solutions. EDEN PRAIRIE, Minn. / Jun 10, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today... Read More

EDEN PRAIRIE, Minn. / May 29, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of... Read More

Announces Commercial Launch of Two New Thrombectomy Devices for the Venous and Arterial Vasculatures: Pounce™ Venous and Pounce LP (Low Profile) EDEN PRAIRIE, Minn. / May 01, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare... Read More

Earnings Conference Call and Webcast Will Begin at 7:00 am (CT) EDEN PRAIRIE, Minn. / Apr 19, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results... Read More

EDEN PRAIRIE, Minn. / Feb 27, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences: The 34th Annual Oppenheimer Healthcare... Read More

EDEN PRAIRIE, Minn. / Feb 01, 2024 / Business Wire / Surmodics, Inc. ( Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2023, and updated its financial guidance for fiscal year ending... Read More

Addition of a low-profile device to the Surmodics Pounce™ thrombectomy platform allows for efficient clot removal in peripheral arteries ranging from 2 mm to 4 mm, such as those found below the knee EDEN PRAIRIE, Minn. / Jan 22, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in... Read More

Virtual Meeting on February 8 at 4 p.m. (CT) EDEN PRAIRIE, Minn. / Jan 16, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 8, at 4 p.m. CT (5 p.m. ET),... Read More

Earnings Conference Call and Webcast Will Begin at 7:00 am (CT) EDEN PRAIRIE, Minn. / Jan 16, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2024 financial results will... Read More

EDEN PRAIRIE, Minn. / Nov 16, 2023 / Business Wire / Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50 th Annual VEITH... Read More

Sundance™ Sirolimus Drug-Coated Balloon exhibits excellent safety profile Primary patency maintained at 24 months in 71.4% of per protocol analysis population EDEN PRAIRIE, Minn. / Nov 16, 2023 / Business Wire / Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the... Read More

EDEN PRAIRIE, Minn. / Nov 14, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 35th Annual Piper Sandler Healthcare Conference, which is being held at the Lotte New... Read More

EDEN PRAIRIE, Minn. / Nov 08, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2023, and introduced its financial guidance for... Read More

35-subject SWING Trial evaluates the safety, performance of Surmodics’ Sundance™ Sirolimus Drug-Coated Balloon Updated safety and performance data for the SWING trial 24-month data will be shared EDEN PRAIRIE, Minn. / Nov 07, 2023 / Business Wire / Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in... Read More

Dr. Peter A. Schneider to share trial results during a Nov. 15 session EDEN PRAIRIE, Minn. / Nov 07, 2023 / Business Wire / Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial... Read More

EDEN PRAIRIE, Minn. / Oct 31, 2023 / Business Wire / Surmodics, Inc. (NASDAQ: SRDX), the global leader in medical device coating technologies, announced the commercial launch of its most advanced hydrophilic medical device coating technology, Preside™ hydrophilic coatings. Preside hydrophilic coatings complement Surmodics’... Read More

Earnings Conference Call and Webcast Will Begin at 7:00 a.m. (CT) EDEN PRAIRIE, Minn. / Oct 10, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that fourth quarter of fiscal year 2023 financial results... Read More

EDEN PRAIRIE, Minn. / Aug 09, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences: The Needham Virtual MedTech & Diagnostics... Read More

EDEN PRAIRIE, Minn. / Aug 02, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2023, and updated its financial guidance for its fiscal year ending... Read More

Earnings Conference Call and Webcast Will Begin at 7:00 a.m. (CT) EDEN PRAIRIE, Minn. / Jul 12, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that third quarter of fiscal year 2023 financial results... Read More

Surmodics to receive $27 million milestone payment from Abbott EDEN PRAIRIE, Minn. / Jun 20, 2023 / Business Wire / Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the receipt of U.S. Food and Drug Administration (FDA)... Read More

Addition to Pounce™ thrombectomy platform with the low-profile (LP) model will allow for efficient clot removal in below-the-knee peripheral arteries (2 mm to 4 mm), expanding the addressable market for the Pounce™ platform EDEN PRAIRIE, Minn. / Jun 14, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider... Read More

EDEN PRAIRIE, Minn. / May 25, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the Jefferies Healthcare Conference, which is being held in New York, NY, from June 7-9,... Read More

EDEN PRAIRIE, Minn. / Apr 26, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year ending... Read More

Registry to enroll up to 500 patients at up to 30 sites, collecting real-world outcomes data for the Pounce™ Thrombectomy System EDEN PRAIRIE, Minn. / Apr 20, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first... Read More

Earnings Conference Call and Webcast Will Begin at 7:00 a.m. (CT) EDEN PRAIRIE, Minn. / Apr 19, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2023 financial results will be released before the market opens on Wednesday, April 26. Management will host a live webcast... Read More

Sublime Radial Access Platform to include the industry’s first suite of torqueable peripheral microcatheters, designed for navigating tortuosity and crossing complex lesions and available for both transradial and transfemoral procedures EDEN PRAIRIE, Minn. / Apr 19, 2023 / Business Wire / Surmodics, Inc. (NASDAQ:SRDX), a... Read More

EDEN PRAIRIE, Minn. / Apr 11, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 22nd Annual Needham Virtual Healthcare Conference, which is being held from April 17-20, 2023. Management will present on Thursday, April 20, at 10:15 a.m. ET (9:15 a.m. CT). A live... Read More

Announces Receipt of Positive Formal FDA Feedback via the Q-Submission Program Substantially reduces the anticipated time and cost needed to receive a PMA EDEN PRAIRIE, Minn. / Mar 28, 2023 / Business Wire / Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it has received formal feedback from the Food and Drug... Read More

EDEN PRAIRIE, Minn. / Mar 08, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences: The 33rd Oppenheimer Annual Healthcare Conference , which is being held virtually March 13‑15, 2023. Management will present on Wednesday, March... Read More

EDEN PRAIRIE, Minn. / Feb 06, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2022, and updated its financial outlook for its fiscal year ending September 30, 2023. First Quarter Fiscal 2023 Financial Summary Total Revenue of $24.9 million, an... Read More

Virtual Meeting on February 9 at 4 p.m. (CT) EDEN PRAIRIE, Minn. / Jan 31, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 9, at 4 p.m. CT (5 p.m. ET), as a virtual meeting. Sue Knight, chair of the board, will lead the meeting, and Gary Maharaj, chief... Read More

Earnings Conference Call and Webcast Will Begin at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. / Jan 26, 2023 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2023 financial results will be released after the market closes on Monday, February 6. Management will host a live webcast... Read More

Surmodics’ proprietary Crystalline Drug Release (CDR) platform enhances sirolimus stability, transfer, and retention in tissue CDR discussed in connection with 12-month data from Surmodics’ SWING trial of the Sundance™ Sirolimus-Coated Balloon Surmodics, Inc. (NASDAQ:SRDX) (the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the... Read More

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received a letter from the U.S. Food and Drug Administration (FDA; the Agency) related to its premarket approval (PMA) application for the SurVeil™ drug-coated balloon (DCB). In the letter, the FDA indicated that the application is not currently approvable, while... Read More

35-subject SWING Trial evaluates the safety, performance of Surmodics’ Sundance™ Sirolimus Drug-Coated Balloon Differentiated capabilities of Surmodics’ crystalline drug release platform to be discussed in connection with SWING trial 12-month data Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Professor Ramon Varcoe... Read More